Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates
Immuneering reported Q3 2026 results with a net loss of $24.2 million ($0.37 per share) and $166.1 million in cash, guiding runway into Q4 2028. The key clinical news is positive: Phase 2 pancreatic cancer follow-up was extended because patients on atebimetinib + mGnP are living longer than projected, with updated N=55 data due in 1H 2027. Phase 3 MAPKeeper 301 enrollment is ahead of schedule, prompting an expansion of the target from 510 to approximately 570 patients and the potential to accelerate the mid-2028 topline readout.
Key figures
- Revenue
- 0
- Guidance
- Cash runway sufficient to fund operations into Q4 2028
- Net loss q3
- 24200000
- Cash position
- 166100000
- Ga expense q3
- 5100000
- Phase2 m Gn P n
- 55
- Rd expense q3
- 20700000
- Phase3 readout
- mid-2028
- Phase2 median os
- 17.3 months
- Cash position dec 2025
- 217000000
- Net loss q3 prior year
- 15000000
- Ga expense q3 prior year
- 4500000
- Phase3 enrollment target
- 570
- Rd expense q3 prior year
- 10900000
- Phase3 enrollment target prior
- 510
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.